MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns
MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns
PR Newswire
SAN FRANCISCO, Nov. 11, 2026
SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Hagens Berman, a national complex securities litigation law firm, announces an investigation into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL). The inquiry focuses on whether Madrigal and senior management misrepresented or concealed material adverse facts concerning the clinical safety data integrity and regulatory compliance of Rezdiffra (resmetirom).
Investors who suffered significant financial losses in Madrigal (NASDAQ: MDGL) securities are encouraged to submit their trading information to Hagens Berman attorneys directly.
- Visit: www.hbsslaw.com/mdgl
- Contact Email: MDGL@hbsslaw.com
- Direct Firm Phone: 844-916-0895
Key Focus of Hagens Berman's MDGL Investigation
The firm's inquiry stems from disclosures made in Madrigal's Quarterly Report filed on Form 10-Q. According to public filings, on October 9, 2026, Dr. Michael Charlton, Madrigal's former Senior Vice President and Head of Clinical Development, filed a whistleblower complaint.
The whistleblower complaint reportedly alleges serious clinical and internal control deficiencies regarding Rezdiffra (resmetirom), including:
- Suppression of Adverse Safety Events: Allegations that senior executive leadership ignored internal warnings regarding suppressed adverse liver-injury data.
- Discrepancies in Efficacy Data: Assertions that presented efficacy results could not be reconciled with underlying source data.
- Improper Board Oversight: Claims that an unblinded member of the Board of Directors was permitted to control the adjudication of clinical outcomes.
Following the revelation of the whistleblower complaint, Madrigal's stock price fell $34.84 per share, or over 8%, to close at $396.32 on heavy trading volume.
"We are investigating the timeline of when Madrigal executives were first alerted to these alleged clinical trial irregularities and whether investors were misled regarding the safety profile and data reliability of Rezdiffra," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in Madrigal and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »
Whistleblowers: Persons with non-public information regarding Madrigal should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email MDGL@hbsslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
SOURCE Hagens Berman Sobol Shapiro LLP
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
3 of the Best Core Stocks to Own
The 10 Best Companies to Invest in Now
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
United States